Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -68.33% is 60% above its 5-year average of -171.01%, near the high end of its 5-year range (-365.56%–-68.33%).
70.87% above its 12-month average of -234.58%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -20.52%.
RETURN ON ASSETS (ROA)
-68.33%
RETURN ON ASSETS (ROA) AVG TTM
-234.58%
RETURN ON ASSETS (ROA) AVG 3Y
-196.81%
RETURN ON ASSETS (ROA) AVG 5Y
-171.01%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+70.87%
CURRENT VS 3Y AVG
+65.28%
CURRENT VS 5Y AVG
+60.04%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.05%
median of 568 covered companies
CURRENT VS SECTOR MEDIAN
-143.64%
vs the sector median at left
Acurx Pharmaceuticals, Inc.
Market Cap
$5.55M
Return on Assets (ROA)
-68.33%
TTM Avg
-234.58%
3Y Avg
-196.81%
5Y Avg
-171.01%
Market Cap
$5.21M
Return on Assets (ROA)
-104.10%
TTM Avg
-116.11%
3Y Avg
-102.15%
5Y Avg
-84.67%
Market Cap
$5.29M
Return on Assets (ROA)
-71.72%
TTM Avg
-29.50%
3Y Avg
-8.92%
5Y Avg
-8.92%
Market Cap
$5.10M
Return on Assets (ROA)
-367.93%
TTM Avg
-1046.51%
3Y Avg
-534.79%
5Y Avg
-427.52%
Market Cap
$5.35M
Return on Assets (ROA)
-1300.98%
TTM Avg
-1108.45%
3Y Avg
-604.75%
5Y Avg
-486.62%
Market Cap
$5.33M
Return on Assets (ROA)
-106.49%
TTM Avg
-259.99%
3Y Avg
-586.63%
5Y Avg
-434.16%
Market Cap
$5.80M
Return on Assets (ROA)
-54.95%
TTM Avg
-72.19%
3Y Avg
-72.80%
5Y Avg
-69.14%
Market Cap
$5.21M
Return on Assets (ROA)
-98.17%
TTM Avg
-154.79%
3Y Avg
-120.06%
5Y Avg
-94.26%
Market Cap
$5.92M
Return on Assets (ROA)
-102.86%
TTM Avg
-76.90%
3Y Avg
-95.53%
5Y Avg
-184.55%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acurx Pharmaceuticals, Inc. (ACXP) | $5.55M | -68.33% | -234.58% | -196.81% | -171.01% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.21M | -104.10% | -116.11% | -102.15% | -84.67% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.29M | -71.72% | -29.50% | -8.92% | -8.92% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.10M | -367.93% | -1046.51% | -534.79% | -427.52% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.35M | -1300.98% | -1108.45% | -604.75% | -486.62% |
| Alzamend Neuro Inc (ALZN)vs › | $5.33M | -106.49% | -259.99% | -586.63% | -434.16% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.80M | -54.95% | -72.19% | -72.80% | -69.14% |
| Imunon, Inc. (IMNN)vs › | $5.21M | -98.17% | -154.79% | -120.06% | -94.26% |
| Lucyd, Inc (LUCY)vs › | $5.92M | -102.86% | -76.90% | -95.53% | -184.55% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.10M | -81.62% | -81.33% | -106.24% | -102.80% |
ROA
-68.3%
ROE
-92.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -103.60% |
| 2024-12-31 | -365.56% |
| 2023-12-31 | -189.10% |
| 2022-12-31 | -128.97% |
| 2021-12-31 | -96.18% |
| 2020-12-31 | -142.68% |
| 2019-12-31 | -234.30% |
